Eagle Pharmaceuticals Inc (EGRX)
0.50
-0.05
(-9.09%)
USD |
OTCM |
Nov 04, 16:00
Eagle Pharmaceuticals Enterprise Value
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 04, 2024 | 61.33M |
| November 01, 2024 | 61.98M |
| October 31, 2024 | 62.63M |
| October 30, 2024 | 61.33M |
| October 29, 2024 | 60.03M |
| October 28, 2024 | 59.38M |
| October 25, 2024 | 62.63M |
| October 24, 2024 | 63.28M |
| October 23, 2024 | 63.15M |
| October 22, 2024 | 63.93M |
| October 21, 2024 | 63.93M |
| October 18, 2024 | 66.53M |
| October 17, 2024 | 63.28M |
| October 16, 2024 | 65.23M |
| October 15, 2024 | 62.63M |
| October 14, 2024 | 62.63M |
| October 11, 2024 | 66.20M |
| October 10, 2024 | 62.63M |
| October 09, 2024 | 66.92M |
| October 08, 2024 | 61.98M |
| October 07, 2024 | 63.28M |
| October 04, 2024 | 66.53M |
| October 03, 2024 | 80.68M |
| October 02, 2024 | 82.63M |
| October 01, 2024 | 101.07M |
| Date | Value |
|---|---|
| September 30, 2024 | 103.28M |
| September 27, 2024 | 106.14M |
| September 26, 2024 | 107.57M |
| September 25, 2024 | 105.23M |
| September 24, 2024 | 105.36M |
| September 23, 2024 | 105.42M |
| September 20, 2024 | 106.27M |
| September 19, 2024 | 110.29M |
| September 18, 2024 | 110.42M |
| September 17, 2024 | 112.37M |
| September 16, 2024 | 109.77M |
| September 13, 2024 | 110.81M |
| September 12, 2024 | 104.58M |
| September 11, 2024 | 103.28M |
| September 10, 2024 | 104.58M |
| September 09, 2024 | 105.49M |
| September 06, 2024 | 110.03M |
| September 05, 2024 | 111.85M |
| September 04, 2024 | 114.71M |
| September 03, 2024 | 115.36M |
| August 30, 2024 | 121.59M |
| August 29, 2024 | 122.89M |
| August 28, 2024 | 122.37M |
| August 27, 2024 | 116.66M |
| August 26, 2024 | 115.88M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
59.38M
Minimum
Oct 28 2024
786.09M
Maximum
Nov 08 2019
429.32M
Average
486.36M
Median
Enterprise Value Benchmarks
| Eli Lilly and Co | 792.96B |
| Verrica Pharmaceuticals Inc | 72.26M |
| NovaBay Pharmaceuticals Inc | 3.645M |
| Palatin Technologies Inc | 13.74M |
| iBio Inc | 9.837M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 5.164M |
| Revenue (Quarterly) | 64.65M |
| Total Expenses (Quarterly) | 54.34M |
| EPS Diluted (Quarterly) | 0.39 |